Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid

Michael J. Kupferminc*, Alan M Peaceman, Dan Aderka, David Wallach, M. Reuben Peyser, Joseph B. Lessing, Michael L Socol

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

OBJECTIVES: We assessed maternal plasma and second-trimester amniotic fluid for levels of the p55 and p75 soluble tumor necrosis factor receptors. STUDY DESIGN: Blood was drawn from 61 healthy pregnant women (group A) before second-trimester genetic amniocentesis, and an aliquot of amniotic fluid was also obtained for this study. An additional blood sample was obtained from 13 of these patients at 36 to 40 weeks' gestation. Twenty-three healthy, nonpregnant women of reproductive age donated blood as a control group (group B). All plasma and amniotic fluid specimens were collectively assayed for the p55 and p75 soluble tumor necrosis factor receptors by specific enzyme-linked immunoassays. Additionally, tumor necrosis factor-α concentrations were measured in second-trimester plasma and amniotic fluid of 22 patients in group A and in all 23 of the nonpregnant women. RESULTS: The p55 and p75 soluble tumor necrosis factor receptors were detectable in all plasma samples from both groups of patients. The concentrations of both soluble receptors were significantly higher in second-trimester plasma compared with nonpregnant measurements (p < 0.01), and the plasma concentrations of both soluble receptors increased significantly from the second to third trimester (p < 0.01). The p55 and p75 soluble tumor necrosis factor receptors were also detectable in all amniotic fluid samples. Tumor necrosis factor-α was detected in the plasma of 15 of 22 patients in the second trimester but in none of the amniotic fluid samples and in none of the plasma saples from the nonpregnant cohort. CONCLUSIONS: Both the p55 and p75 soluble tumor necrosis factor receptors are physiologic constituents of second-trimester maternal plasma and amniotic fluid. Concentrations are elevated in pregnancy and further increase from the second to third trimester.

Original languageEnglish (US)
Pages (from-to)900-905
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume173
Issue number3 PART 1
DOIs
StatePublished - Jan 1 1995

Fingerprint

Tumor Necrosis Factor Receptors
Second Pregnancy Trimester
Amniotic Fluid
Mothers
Third Pregnancy Trimester
Tumor Necrosis Factor-alpha
Pregnancy
Amniocentesis
Immunoenzyme Techniques
Pregnant Women
Control Groups

Keywords

  • Soluble tumor necrosis factor receptors
  • tumor necrosis factor

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Kupferminc, Michael J. ; Peaceman, Alan M ; Aderka, Dan ; Wallach, David ; Peyser, M. Reuben ; Lessing, Joseph B. ; Socol, Michael L. / Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid. In: American Journal of Obstetrics and Gynecology. 1995 ; Vol. 173, No. 3 PART 1. pp. 900-905.
@article{ce00e9452c1d44d5a8388af556b4f9f5,
title = "Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid",
abstract = "OBJECTIVES: We assessed maternal plasma and second-trimester amniotic fluid for levels of the p55 and p75 soluble tumor necrosis factor receptors. STUDY DESIGN: Blood was drawn from 61 healthy pregnant women (group A) before second-trimester genetic amniocentesis, and an aliquot of amniotic fluid was also obtained for this study. An additional blood sample was obtained from 13 of these patients at 36 to 40 weeks' gestation. Twenty-three healthy, nonpregnant women of reproductive age donated blood as a control group (group B). All plasma and amniotic fluid specimens were collectively assayed for the p55 and p75 soluble tumor necrosis factor receptors by specific enzyme-linked immunoassays. Additionally, tumor necrosis factor-α concentrations were measured in second-trimester plasma and amniotic fluid of 22 patients in group A and in all 23 of the nonpregnant women. RESULTS: The p55 and p75 soluble tumor necrosis factor receptors were detectable in all plasma samples from both groups of patients. The concentrations of both soluble receptors were significantly higher in second-trimester plasma compared with nonpregnant measurements (p < 0.01), and the plasma concentrations of both soluble receptors increased significantly from the second to third trimester (p < 0.01). The p55 and p75 soluble tumor necrosis factor receptors were also detectable in all amniotic fluid samples. Tumor necrosis factor-α was detected in the plasma of 15 of 22 patients in the second trimester but in none of the amniotic fluid samples and in none of the plasma saples from the nonpregnant cohort. CONCLUSIONS: Both the p55 and p75 soluble tumor necrosis factor receptors are physiologic constituents of second-trimester maternal plasma and amniotic fluid. Concentrations are elevated in pregnancy and further increase from the second to third trimester.",
keywords = "Soluble tumor necrosis factor receptors, tumor necrosis factor",
author = "Kupferminc, {Michael J.} and Peaceman, {Alan M} and Dan Aderka and David Wallach and Peyser, {M. Reuben} and Lessing, {Joseph B.} and Socol, {Michael L}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0002-9378(95)90363-1",
language = "English (US)",
volume = "173",
pages = "900--905",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3 PART 1",

}

Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid. / Kupferminc, Michael J.; Peaceman, Alan M; Aderka, Dan; Wallach, David; Peyser, M. Reuben; Lessing, Joseph B.; Socol, Michael L.

In: American Journal of Obstetrics and Gynecology, Vol. 173, No. 3 PART 1, 01.01.1995, p. 900-905.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid

AU - Kupferminc, Michael J.

AU - Peaceman, Alan M

AU - Aderka, Dan

AU - Wallach, David

AU - Peyser, M. Reuben

AU - Lessing, Joseph B.

AU - Socol, Michael L

PY - 1995/1/1

Y1 - 1995/1/1

N2 - OBJECTIVES: We assessed maternal plasma and second-trimester amniotic fluid for levels of the p55 and p75 soluble tumor necrosis factor receptors. STUDY DESIGN: Blood was drawn from 61 healthy pregnant women (group A) before second-trimester genetic amniocentesis, and an aliquot of amniotic fluid was also obtained for this study. An additional blood sample was obtained from 13 of these patients at 36 to 40 weeks' gestation. Twenty-three healthy, nonpregnant women of reproductive age donated blood as a control group (group B). All plasma and amniotic fluid specimens were collectively assayed for the p55 and p75 soluble tumor necrosis factor receptors by specific enzyme-linked immunoassays. Additionally, tumor necrosis factor-α concentrations were measured in second-trimester plasma and amniotic fluid of 22 patients in group A and in all 23 of the nonpregnant women. RESULTS: The p55 and p75 soluble tumor necrosis factor receptors were detectable in all plasma samples from both groups of patients. The concentrations of both soluble receptors were significantly higher in second-trimester plasma compared with nonpregnant measurements (p < 0.01), and the plasma concentrations of both soluble receptors increased significantly from the second to third trimester (p < 0.01). The p55 and p75 soluble tumor necrosis factor receptors were also detectable in all amniotic fluid samples. Tumor necrosis factor-α was detected in the plasma of 15 of 22 patients in the second trimester but in none of the amniotic fluid samples and in none of the plasma saples from the nonpregnant cohort. CONCLUSIONS: Both the p55 and p75 soluble tumor necrosis factor receptors are physiologic constituents of second-trimester maternal plasma and amniotic fluid. Concentrations are elevated in pregnancy and further increase from the second to third trimester.

AB - OBJECTIVES: We assessed maternal plasma and second-trimester amniotic fluid for levels of the p55 and p75 soluble tumor necrosis factor receptors. STUDY DESIGN: Blood was drawn from 61 healthy pregnant women (group A) before second-trimester genetic amniocentesis, and an aliquot of amniotic fluid was also obtained for this study. An additional blood sample was obtained from 13 of these patients at 36 to 40 weeks' gestation. Twenty-three healthy, nonpregnant women of reproductive age donated blood as a control group (group B). All plasma and amniotic fluid specimens were collectively assayed for the p55 and p75 soluble tumor necrosis factor receptors by specific enzyme-linked immunoassays. Additionally, tumor necrosis factor-α concentrations were measured in second-trimester plasma and amniotic fluid of 22 patients in group A and in all 23 of the nonpregnant women. RESULTS: The p55 and p75 soluble tumor necrosis factor receptors were detectable in all plasma samples from both groups of patients. The concentrations of both soluble receptors were significantly higher in second-trimester plasma compared with nonpregnant measurements (p < 0.01), and the plasma concentrations of both soluble receptors increased significantly from the second to third trimester (p < 0.01). The p55 and p75 soluble tumor necrosis factor receptors were also detectable in all amniotic fluid samples. Tumor necrosis factor-α was detected in the plasma of 15 of 22 patients in the second trimester but in none of the amniotic fluid samples and in none of the plasma saples from the nonpregnant cohort. CONCLUSIONS: Both the p55 and p75 soluble tumor necrosis factor receptors are physiologic constituents of second-trimester maternal plasma and amniotic fluid. Concentrations are elevated in pregnancy and further increase from the second to third trimester.

KW - Soluble tumor necrosis factor receptors

KW - tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0029095844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029095844&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(95)90363-1

DO - 10.1016/0002-9378(95)90363-1

M3 - Article

VL - 173

SP - 900

EP - 905

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3 PART 1

ER -